Cathepsin L pseudogene 2 (CTSLP2)

Cathepsin L pseudogene 2 is classified as a pseudogene in the human genome and is designated by the gene symbol CTSLP2[1][4][7]. Unlike its homolog, cathepsin L (CTSL), which is a cysteine protease with major roles in proteolysis, antigen processing, and disease processes, CTSLP2 does not encode a functional protein. Pseudogenes may be transcribed but generally lack coding potential due to sequence mutations and are not translated into functional proteins. Some pseudogenes can have regulatory effects on their protein-coding relatives (for example, through RNA-mediated mechanisms), but there is no direct evidence for functional roles or disease associations specific to CTSLP2 in current scientific resources[4][10]. CTSLP2, therefore, is not recognized as a therapeutic target, enzyme, receptor, transporter, or related drug target. If you are seeking information relevant to therapeutic targeting or molecular pharmacology, the actual enzymatic protein cathepsin L (CTSL), and not CTSLP2, would be the appropriate entity to study[2][3][5]. Summary of issues: - CTSLP2 is a pseudogene, not a coding gene or protein. - It does not serve as a druggable target, and has no known biological or disease-modifying functions[1][4][10]. - There are no drugs targeting CTSLP2, nor mechanisms of action, nor uses as a biomarker, nor recognized safety or therapeutic concerns. For research on cathepsin function or as a drug target, refer to cathepsin L (CTSL), not CTSLP2.

Other names

bA342C24.4bA144G6.6